Form 483

Sanofi-Aventis Deutschland GmbH Form 483, 2017-03-03

FDA issued a Form 483 to Sanofi-Aventis Deutschland GmbH on 2017-03-03 with 4 public-safe observations.

483· Form 483 issuedHuman Drugs4 observations

Sanofi-Aventis Deutschland GmbH · Frankfurt Am Main, Germany · Issued March 3, 2017

Overview

  • 4 public-safe observations are available for this inspection.
  • 4 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

3 Mar 2017
21 CFR 211.113(b)

Validation lacking for sterile drug products

Cited by Junho Pak

3 Mar 2017
21 CFR 211.192

Written record of investigation incomplete

Cited by Junho Pak

3 Mar 2017
21 CFR 211.42(c)(10)(vi)

Equipment to control conditions

Cited by Junho Pak

3 Mar 2017
21 CFR 211.84(d)(2)

Establish reliability of supplier's C of A

Cited by Junho Pak

Inspected site

SDSanofi-Aventis Deutschland GmbHFrankfurt Am Main, Germany

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.113(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)(10)(vi)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 4 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere